From Yahoo Finance: 2025-04-02 07:02:00

Amneal Pharmaceuticals and Shilpa Medicare have launched Boruzu, a new presentation of bortezomib for multiple myeloma and mantle cell lymphoma in the US. It is the first ready-to-use injection for these conditions, simplifying the administration process. Boruzu references branded Velcade and has common side effects like anaemia and neuropathy.

Shilpa created the molecule, while Amneal manages manufacturing and commercialization. Boruzu’s launch in the US is part of Amneal’s strategy to build a leading injectables portfolio. The company aims to streamline pharmacy preparation steps for clinicians and facilitate reimbursement through a unique J-code.

Amneal focuses on biosimilars, injectables, and branded pharmaceuticals in therapeutic areas like endocrine and CNS disorders. It also distributes products to the US federal government and various markets through its AvKARE segment. Shilpa is an integrated pharmaceutical group with interests in peptides, oncology, and APIs.

In August 2024, the US FDA approved Amneal’s Crexont extended-release capsules for Parkinson’s disease treatment. The collaboration between Amneal and Shilpa to introduce Boruzu in the US marks a significant advancement in cancer treatment options.



Read more at Yahoo Finance: Amneal and Shilpa introduce Boruzu in US for cancer treatment